On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Experimental in this US library; foreign clinical reports do not establish US approval of a supplied preparation.
Immune-marker hypothesis
The respiratory report examined cellular and other immune parameters. Such markers describe a proposed immunomodulatory effect, not a validated broad immune reset. [1]
What the evidence shows
Perioperative study
A 2011 Russian-language randomized, double-blind trial studied intranasal thymogen before surgery for abdominal or retroperitoneal cancers in older patients. The abstract reports improved immune measures and fewer complications, but does not provide group sizes or absolute event rates. [2]
Respiratory report
A 1994 report described 33 patients with chronic obstructive bronchitis receiving thymogen within multimodal treatment. Changes in immune measures cannot isolate thymogen’s contribution from accompanying care or establish durable respiratory benefit. [1]
What remains unknown
Independent confirmation, reproducible effect sizes and systematic long-term safety are missing from these reports. Benefit for healthy people or routine infection prevention cannot be assumed.
Safety
Limited adverse-event evidence
The available perioperative abstract does not provide enough safety detail to estimate uncommon reactions or interactions with modern treatments. [2]
Manufacturing remains relevant
Compounded products are not FDA approved; their quality assessment is separate from an ingredient’s biological rationale. [3]
Route-specific evidence
The surgical study used an intranasal preparation. It does not establish equivalent effects or safety for other formulations. [2]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [4]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [5]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is this interchangeable with thymosin alpha-1?
No. The names refer to different substances and clinical evidence cannot be transferred between them.
What should I ask about a proposed benefit?
Ask for the exact human study, comparison group, measured outcome and how closely the supplied preparation matches it.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Thymogen in chronic obstructive bronchitis1994 Russian-language clinical report in 33 patients receiving multimodal treatment.
- Thymogen in elderly surgical oncology patients2011 Russian-language randomized double-blind placebo-controlled study; abstract does not supply group sizes or absolute complication rates.
- FDA: compounding questions and answersFDA explanation of compounded-drug approval and quality differences; accessed September 9, 2026.
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.